Who are SynApps Solutions?
At SynApps Solutions we specialise in Enterprise Content Management (ECM), Vendor Neutral Archive (VNA) and Healthcare technologies. As the UK Distributor for Veolity developed by MeVis Medical Solutions AG, we help radiologists review and validate lung CT scans at speed. Veolity is a dedicated software package for lung cancer diagnostics offering efficient and effective reading of lung cancer screening chest CT scans. Veolity includes CAD, automatic segmentation, integration of prior findings, and an optimised workflow for structured reporting.
How has SynApps Solutions improved outcomes for the NHS and patients?
Specifically, within the lung screening field the deployment of our lung cancer diagnostics solution is helping to streamline the process of analysing and reporting of lung cancer scans and propagate findings from earlier scans. This is helping to broaden the rollout of lung health checks across the community and deliver improved access to patients.
However, Veolity is also perfectly suitable to be used for incidental nodule management: volumetric quantification of nodules on double-click, automatic temporal comparison and growth assessment due to automatic registration, an automated workflow that helps to reduce your reading times, and finally the integrated AI-based CAD can detect even small pulmonary nodules that may have been initially overlooked.
What has been your greatest achievement to date? And were there any measurable outcomes that accompanied this achievement?
It is still early days in the deployment of lung screening within the NHS for measurable outcomes to be assessed. However, it can be said Veolity has provided a real example of how the deployment of A.I. based technology can provide improved tools to clinicians than those previously available. We are pleased with the positive reception the product has received to date.
How many organisations/clients currently utilise the service/solution across the UK?
We have 5 NHS sites live at this time. We are seeing strong interest from other NHS sites at this time.
Is there anything you would like to make delegates aware of ahead of the NHS Long Term Plan 2020 conference on 29th April?
The recent government review of national cancer screening revealed that technology will play a key role if screening is to be provided on the scale and standard required by such programmes. However, the ever-broadening choice of screening programmes also requires a step change in the way patient engagement is provided, so that patients have more control of where, when and how they get access to these services and the subsequent results. A coordinate solution providing online patient engagement is key if follow-up screening appointments (eg. 3 months later) are to be met in a timely manner.
What do you feel are the key points delegates need to digest when considering a partnership with SynApps Solutions?
At SynApps we are a key provider of integrated healthcare solutions which can specifically benefit hospitals wanting to initiate a screening programme.
We are the distributor for the Veolity lung screening solution in the UK, but can also offer PACS, RIS and VNA/ECM solutions.
If you would like to learn more about SynApps Solutions please visit https://www.synapps-solutions.com/
コメント